Back to top

biotechs: Archive

Zacks Equity Research

Immunomedics Gets CRL From FDA for Breast Cancer Candidate

Immunomedics (IMMU) receives a CRL from the FDA pertaining to the BLA for its lead breast cancer candidate, sacituzumab govitecan.

AZN RHHBY CLVS IMMU

Zacks Equity Research

Ligand (LGND) Takes a Hit on Citron's Negative Research Report

Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.

LLY BMY LGND SAGE

Zacks Equity Research

Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod

Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.

ACAD EXEL VNDA AMGN

Zacks Equity Research

Regeneron (REGN) Sails Steady on Label Expansion of Drugs

Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.

BAYRY SNY REGN CELG

Tracey Ryniec

Will Dividend Stocks be the Hot Stocks of 2019?

With growth stocks sputtering to end 2018, investors seem poised to look in a new direction.

ABBV T VZ GILD OXY

Zacks Equity Research

Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer

Exelixis (EXEL) gets FDA approval for Cabometyx tablets for patients with hepatocellular carcinoma (liver cancer), who have been previously treated with Nexavar.

RHHBY BMY BAYRY EXEL

Zacks Equity Research

Pfizer Gets FDA's Priority Review for Rare Disease Candidate

FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.

PFE ALNY IONS AKCA

Zacks Equity Research

5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019

Exelixis (EXEL) lead drug, Cabometyx continues to perform well.

BMY RHHBY MRK EXEL

Zacks Equity Research

Tilray Shares Rally as Investor Plans Not to Sell Shares

Tilray (TLRY) gains after Privateer Holdings decides not to sell shares in the first half of 2019.

NVS BUD CRON CGC TLRY

Sanghamitra Saha

Top ETFs of Last Week

These ETFs have had a strong last week.

DIA SBIO SPY QQQ EBIZ MJ XKST BMLP

Sweta Killa

Best & Worst Performing ETFs to Start 2019

We have highlighted some ETFs that are off to a good start in 2019 and some that have had a rough start.

XES MJ ARKG VXXB BDRY DWSH

Zacks Equity Research

ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.

RHHBY ACOR VNDA ASLN

Zacks Equity Research

Options Traders Expect Huge Moves in Ferroglobe (GSM) Stock

Investors need to pay close attention to Ferroglobe (GSM) stock based on the movements in the options market lately.

GSM

Zacks Equity Research

NASH Space in Focus in 2019 as Firms Look to Diversify

NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.

PFE RHHBY MRK NVS VKTX GILD ICPT

Zacks Equity Research

Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here's Why

Puma Biotech's (PBYI) only marketed drug, Nerlynx, is suffering low sales due to higher patient discontinuations.

LLY RHHBY NVS PBYI

Zacks Equity Research

Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer

Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.

PFE BMY AMRN CELG

Kinjel Shah

4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019

Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.

JNJ GSK PFE BMY MRK LLY CELG

Zacks Equity Research

Athenex Completes Enrollment Target for Breast Cancer Study

Athenex (ATNX) has completed target enrollment in the Oraxol phase III study in metastatic breast cancer on schedule.

RHHBY PFE PBYI ATNX

Zacks Equity Research

Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect

Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.

ACOR VNDA INO MYL

Zacks Equity Research

Moderna (MRNA) Announces Pipeline Progress, Shares Rise

Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.

MRK AZN VRTX MRNA

Zacks Equity Research

Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan

Amgen (AMGN) gets approval in Japan for osteoporosis candidate, Evenity.

AMGN VNDA INO AEZS

Zacks Equity Research

Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus

It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.

REGN GILD ALNY CELG BIIB LOXO SAGE

Zacks Equity Research

Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%

Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

MRTX ACOR

Zacks Equity Research

Celgene (CELG) Provides Guidance for 2019, Updates Pipeline

Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.

BMY BLUE XLRN CELG

Zacks Equity Research

Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results

Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.

SNY GSK EBS VNDA